Abstract
Ever since Huggins and Hodges won a Nobel Prize in 1966 for their work describing the relationship between testosterone and prostate cancer, androgen deprivation has continued to be an important component in the treatment of prostate cancer. Refinements in the therapy have occurred in the past 50 years, yet controversies still exist. This review details the controversies and advances in androgen deprivation for prostate cancer including: neoadjuvant androgen deprivation, combined androgen blockade, early versus late androgen deprivation treatment, intermittent versus continuous androgen deprivation monotherapy, anti-androgen monotherapy, anti-androgen and 5-alpha reductase inhibitor combinations, androgen deprivation with periodic intravenous bisphosphonate infusions, and androgen deprivation in conjunction with chemotherapy.
Keywords: chemotherapy, intravenous bisphosphonates, Prostatic neoplasm, androgen deprivation, neoadjuvant therapy, combined androgen blockade, early hormonal treatment, anti-androgen monotherapy
Current Pharmaceutical Design
Title: Controversies of Androgen Ablation Therapy for Metastatic Prostate Cancer
Volume: 12 Issue: 7
Author(s): Shandra S. Wilson and E. D. C.
Affiliation:
Keywords: chemotherapy, intravenous bisphosphonates, Prostatic neoplasm, androgen deprivation, neoadjuvant therapy, combined androgen blockade, early hormonal treatment, anti-androgen monotherapy
Abstract: Ever since Huggins and Hodges won a Nobel Prize in 1966 for their work describing the relationship between testosterone and prostate cancer, androgen deprivation has continued to be an important component in the treatment of prostate cancer. Refinements in the therapy have occurred in the past 50 years, yet controversies still exist. This review details the controversies and advances in androgen deprivation for prostate cancer including: neoadjuvant androgen deprivation, combined androgen blockade, early versus late androgen deprivation treatment, intermittent versus continuous androgen deprivation monotherapy, anti-androgen monotherapy, anti-androgen and 5-alpha reductase inhibitor combinations, androgen deprivation with periodic intravenous bisphosphonate infusions, and androgen deprivation in conjunction with chemotherapy.
Export Options
About this article
Cite this article as:
Wilson S. Shandra and C. D. E., Controversies of Androgen Ablation Therapy for Metastatic Prostate Cancer, Current Pharmaceutical Design 2006; 12 (7) . https://dx.doi.org/10.2174/138161206776056056
DOI https://dx.doi.org/10.2174/138161206776056056 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting
Current Gene Therapy Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets Recent Advances in the Medicinal Chemistry of α-Aminoboronic Acids, Amine-Carboxyboranes and Their Derivatives
Mini-Reviews in Medicinal Chemistry Molecular Basis of Therapeutic Strategies for Breast Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Anticancer Activity of Ferrocenylthiosemicarbazones
Anti-Cancer Agents in Medicinal Chemistry Alternative Spliced Variants as Biomarkers of Colorectal Cancer
Current Drug Metabolism Highlights on Medical Treatment of Uterine Fibroids
Current Pharmaceutical Design Retinoic Acid Metabolism and Mechanism of Action: A Review
Current Drug Metabolism Regulation of Iron Absorption in Hemoglobinopathies
Current Molecular Medicine Engineered Peptides for Applications in Cancer-Targeted Drug Delivery and Tumor Detection
Mini-Reviews in Medicinal Chemistry The Role of Saffron in Attenuating Age-related Oxidative Damage in Rat Hippocampus
Recent Patents on Food, Nutrition & Agriculture An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design In Vivo Transdermal Delivery of Leuprolide Using Microneedles and Iontophoresis
Current Pharmaceutical Biotechnology An Overview of Emerging Immunotargets of Genitourinary Tumors
Current Drug Targets Peptide-Based Nanostructures for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Immune Cells Act as Promising Targets for the Treatment of Bone Metastasis
Recent Patents on Anti-Cancer Drug Discovery Readjusting the Glucocorticoid Balance: An Opportunity for Modulators of 11β -Hydroxysteroid Dehydrogenase Type 1 Activity?
Endocrine, Metabolic & Immune Disorders - Drug Targets Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets